Circumvention of adriamycin resistance: effect of 2-methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells.
The effect of vitamin K3 (2-methyl-1,4-naphthoquinone) on Adriamycin (ADR) induced growth inhibition of drug sensitive and multidrug resistant P388 leukemia cells was evaluated. Exposure to ADR concentrations of 100-5000 ng simultaneously with 1 microM vitamin K3 elicited an enhanced inhibition of tumor cell survival. The effect of treatment with ADR alone, or in combination with vitamin K3 on DNA and RNA biosynthesis in the sensitive and resistant tumor cells, was also assessed. DNA and RNA biosynthesis inhibition was increased in P388/S (the parental cell line) and P388/ADR cells (the ADR resistant cell line which exhibits the multidrug resistant (MDR) phenotype) exposed to ADR after pretreatment for 3 h with vitamin K3. Concurrent administration in vivo of vitamin K3 and ADR illustrated a therapeutically significant increase (P less than 0.05) in the life span of sensitive and resistant tumor cell bearing animals. Vitamin K3 caused a depletion of the intracellular glutathione (GSH) levels in P388/S and P388/ADR leukemia cells but at concentrations greater than those that enhanced ADR cytotoxicity. Pretreatment of the tumor cells with 1 microM vitamin K3 induced a 35-50% (P less than 0.001) elevation in the intracellular ADR accumulation in MDR P388 leukemia cells, while such an effect was absent in P388/S tumor cells. DNA binding studies performed utilizing calf thymus DNA, indicated that vitamin K3 enhanced the intercalation potential of ADR and also altered the equilibrium between the free and bound form of ADR in a cell free system. These factors and their possible effects on the potentiation of ADR cytotoxicity and the therapeutic significance of utilizing vitamin K3 as an adjuvant in the chemotherapy of MDR tumors is discussed.
Parekh
H K
HK
Chemotherapy Division, Tata Memorial Centre, Parel, Bombay, India.
Mansuri-Torshizi
H
H
Srivastava
T S
TS
Chitnis
M P
MP
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D004247:DNA / Q000378:metabolism; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004317:Doxorubicin / Q000008:administration & dosage* / Q000378:metabolism; D004351:Drug Resistance; D066298:In Vitro Techniques; D007941:Leukemia P388; D007942:Leukemia, Experimental / Q000188:drug therapy; D051379:Mice; D012334:RNA, Neoplasm / Q000096:biosynthesis; D013057:Spectrum Analysis; D014407:Tumor Cells, Cultured; D014812:Vitamin K / Q000494:pharmacology*
D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D014812:Vitamin K; D004317:Doxorubicin; D004247:DNA